CTI Finds Pixuvri’s Conditional Authorization Is Not Enough To Win NICE Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
In an early stage decision, NICE rejects Pixuvri for multiply relapsed or refractory aggressive non-Hodgkin's lymphoma, citing lack of evidence and cost-effectiveness.